3rd Apr 2023 3:00 pm |
RNS |
Total Voting Rights |
3rd Apr 2023 7:00 am |
RNS |
Ultomiris recommended for NMOSD EU approval |
30th Mar 2023 7:00 am |
RNS |
AstraZeneca completes KYM agreement for CMG901 |
27th Mar 2023 11:00 am |
RNS |
Director/PDMR Shareholding |
22nd Mar 2023 11:00 am |
RNS |
Notice of AGM |
9th Mar 2023 7:00 am |
RNS |
Imfinzi improved EFS in resectable lung cancer |
8th Mar 2023 11:01 am |
RNS |
Director/PDMR Shareholding |
8th Mar 2023 11:00 am |
RNS |
Director/PDMR Shareholding |
6th Mar 2023 7:00 am |
RNS |
Enhertu DESTINY-PanTumor02 shows positive results |
1st Mar 2023 3:00 pm |
RNS |
Total Voting Rights |
1st Mar 2023 7:00 am |
RNS |
AstraZeneca prices a $2.25bn bond offering |
24th Feb 2023 6:15 pm |
RNS |
AstraZeneca prices a EUR1.5bn bond offering |
24th Feb 2023 2:05 pm |
RNS |
AstraZeneca acquires CinCor for cardiorenal asset |
24th Feb 2023 11:00 am |
RNS |
Director/PDMR Shareholding |
23rd Feb 2023 7:00 am |
RNS |
AstraZeneca enters agreement with KYM for CMG901 |
22nd Feb 2023 7:10 am |
RNS |
Filing of Form 20-F with SEC |
21st Feb 2023 11:00 am |
RNS |
Annual Financial Report |
13th Feb 2023 2:01 pm |
RNS |
Director/PDMR Shareholding |
13th Feb 2023 2:00 pm |
RNS |
Director/PDMR Shareholding |
9th Feb 2023 7:00 am |
RNS |
Final Results |
1st Feb 2023 3:00 pm |
RNS |
Total Voting Rights |
26th Jan 2023 6:15 pm |
RNS |
Update on Evusheld US EUA |
16th Jan 2023 7:00 am |
RNS |
Acquisition of Neogene Therapeutics completed |
11th Jan 2023 1:00 pm |
RNS |
Airsupra (PT027) approved in US for asthma |
9th Jan 2023 7:00 am |
RNS |
AstraZeneca acquire CinCor for cardiorenal asset |
3rd Jan 2023 3:00 pm |
RNS |
Total Voting Rights |
30th Dec 2022 11:00 am |
RNS |
Director/PDMR Shareholding |
28th Dec 2022 7:05 am |
RNS |
Calquence Japan approval for treatment-naïve CLL |
28th Dec 2022 7:00 am |
RNS |
Imfinzi, Imjudo approved in Japan for 3 cancers |
21st Dec 2022 7:05 am |
RNS |
Lynparza approved in EU for prostate cancer |
21st Dec 2022 7:00 am |
RNS |
Imfinzi approved in EU for biliary tract cancer |
19th Dec 2022 7:20 am |
RNS |
Enhertu recommended for EU approval in HER2-low BC |
19th Dec 2022 7:15 am |
RNS |
Enhertu approved in EU for gastric cancer |
19th Dec 2022 7:10 am |
RNS |
Imfinzi + Imjudo recommended for approvals in EU |
19th Dec 2022 7:05 am |
RNS |
Update on Imfinzi PEARL trial |
19th Dec 2022 7:00 am |
RNS |
Forxiga CHMP opinion for symptomatic chronic HF |
15th Dec 2022 7:00 am |
RNS |
Update on US review of Lynparza PROpel sNDA |
8th Dec 2022 1:30 pm |
RNS |
Capivasertib PFS in HR-positive breast cancer |
1st Dec 2022 3:00 pm |
RNS |
Block listing Interim Review |
1st Dec 2022 3:00 pm |
RNS |
Total Voting Rights |